Vaccine studies in Turkey

[Bogeyman]

Domestic vaccine production work scope will have the highest biosafety level BSL-4 laboratories established in Adiyaman in Turkey.


According to the statement made by the Ministry of Industry and Technology , regarding President Recep Tayyip Erdogan 's new type of coronavirus (Kovid-19) vaccine, "The infrastructure of a private sector company is made suitable for the production of the vaccine." Following in his eyes, TUBITAK-Kovid has been translated into 19 studies conducted in the framework of Turkey Platform.

There are 17 projects
Turkey, all quickly are continuing studies on the vaccine will be effective against all the world like Kovid-19. TUBITAK Turkey Kovid-19 Platform scientists working on a total of 17 projects, including vaccines and drugs under the roof, struggling to get results soon. One of these studies is carried out in Adıyaman.

Minister Varank visited Vetal
President Erdogan in 2021 in the first months of the pointed-out project of one sustained by Adiyaman from Industry and Technology Minister Mustafa Varank visited Vetal AŞ that made the vaccine development work in the city, most will have a biosafety level BSL-4 in Turkey He made examinations in the construction of his laboratory.


During his visit to Minister Varank, Adiyaman Governor Mahmut Çuhadar, President of TÜBİTAK Prof. Dr. Hasan Mandal, AK Party Adıyaman Deputies Ahmet Aydın, Halil Fırat, Yakup Taş and Fatih Toprak and Adiyaman University Rector Prof. Dr. Mehmet Turgut accompanied him.

Has 17 laboratories
TUBITAK and Vetal firm cooperation in new types koronavirüsl struggle within the framework of that statement after the inspection of the factory where activities Ministers Varank, veterinary vaccines, that one of Adiyaman from the company with Turkey's best infrastructure in the production said, he said that with the company's biosecurity 17 laboratory.

Stating that Vetal company has exported veterinary vaccines produced by Varank, Varank stated that the company also conducts antiserum studies with Adıyaman University.

Studies are carried out with the great effort of scientists
Kovid-19 reminded that they take important measures from entering Turkey borders Varank In this context, the TUBITAK-19 Kovid stated that Turkey constitutes Platform.


Vaccine projects it highlights a significant distance catheter Varank, "Kovid-19 launched under the umbrella of TUBITAK Turkey Our Platform drug and vaccine development project is continuing with great determination and sciences outstanding efforts of our people." used the expression.

"We came to clinical phase studies in 3 vaccine projects"
Stating that animal experiments were completed in 2 projects within the scope of vaccine development studies, Varank gave the following information:

"Our professor, Prof. Dr. Osman Erganiş from Selçuk University has reached the last point in animal experiments in the study he conducted with Vetal. In the next stage, he will submit his files to our Ministry of Health. Thus, we came to clinical phase studies in 3 vaccine projects on our platform. Of course, besides the development of these vaccines, mass production also very important. These we visit all our companies have the infrastructure can produce in Turkey. Vetal also an important candidate. here in our facility that can be used very comfortable for the production of human vaccine authorized by the Ministry of Health. we're also negotiating with the Health Ministry teams were viewed by visiting here. Certification After the studies are completed, we want to produce our vaccines, which are at the trial stage on humans, and move to a new stage.

"We will be able to produce vaccines ourselves and offer them to our citizens"
Emphasizing that they want to offer a local and national vaccine to the service of the people, Varank said, "I hope we will be able to produce vaccines that will heal our country and offer them to our citizens." used the expression.

Stating that they are working in coordination with the Ministry of Health in vaccination studies, Varank said:

"The file of our vaccines, the animal trials of which have been completed, have been submitted to the Ministry of Health. The necessary investigations are carried out quickly under the leadership of our minister. We believe that we will switch to Phase-1 in a very short time, as long as the existing examination processes are completed as soon as possible. We believe that we will be able to start human trials in a short time. "

Adıyaman aşı üretimine hazır

Yerli aşı üretimi çalışmaları kapsamında Türkiye'de en yüksek biyogüvenlik seviyesine sahip olacak BSL-4 laboratuvarı Adıyaman'da kuruluyor. - Anadolu Ajansı

www.aa.com.tr

 

[Luwian]

great news - that's what needs to be " able to produce vaccines ourselves and offer them to our citizens" as well to offer them to the rest of world community those who can't afford by own.

 

[Bogeyman]

Researchers working in the laboratory enzyme recognition site in Gebze Technical University, plaster of leukemia patients was obtained for the enzyme asparaginase arms from abroad to produce in Turkey.

Acute Lymphoblastic most common type of cancer in childhood leukemia (ALL) is used in the treatment of disease and the active ingredient of the drug imported from abroad enzyme asparaginase work began to be produced in Turkey.

At the Binay Enzyme Recognition Center Laboratories (BERC) operating under Gebze Technical University (GTÜ), scientific research is carried out to obtain locally derived enzymes, which are widely used in sectors such as chemistry, medicine, leather, paper, food, and textiles.

Previously imported many enzyme laboratory personnel providing the services industry, used in the treatment of ALL disease and abroad imported drugs is the active ingredient in the move to produce in Turkey, the enzyme asparaginase.

Within the scope of the European Cooperation in Science and Technology (COST) Program, the international project, which is entitled to be supported by TUBITAK, aims to produce and launch the drug in 3 years.

"We have offered many enzymes that we have produced before to the service of the industry"

Head of GTÜ Bioengineering Department Assoc. Dr. Barış Binay told the AA correspondent that they carried out many studies in the enzyme recognition laboratory operating under the umbrella of the university, from cloning to modeling of enzymes and production.

Stating that they have offered many enzymes they previously produced in the laboratory to the service of the industry, Binay stated that the project they prepared for the production of the asparaginase enzyme used in the treatment of ALL disease was entitled to receive support from TÜBİTAK within the scope of the COST program.

Binay pointed out that in the pharmaceutical industry, which has gone through many different periods, there has been a shift to biotechnological drugs, especially with the recombinant DNA technology developed in the 1970s, and stated that biotechnological drugs are obtained at high purity in environmentally friendly processes.

"The cost of these drugs for our country is very high"

Describing that drugs designed especially in certain disease groups such as cancer prevent the growth of the cell by stopping the proliferation of DNA, Binay said, "Here, enzymes come to meet just such a drug. Enzymes can offer a solution when you want to produce the drug active substance at low cost and in environmentally friendly processes." he spoke.

Assoc. Dr. Emphasizing that some enzymes are used as drug active ingredients directly in the cell, Binay continued his words as follows:

"In our country, we see that 8 of the important drugs called enzyme-based are supplied from abroad and offered to the service of medicine. Many enzyme-based drugs are imported, but 8 of them stand out. The prominence of these is due to the fact that they are used in rare diseases. The cost of these drugs to our country is quite high. One of them is the drug with asparaginase active ingredient, usually supplied from Japan, Canada and 2 European countries. "

Explaining that they focused on the asparaginase enzyme in the project they are working on, Binay said, "This enzyme is used in the treatment of acute lymphoblastic leukemia, which is seen in children and known as ALL. This drug used in the treatment of ALL has very high costs for both the Ministry of Health and the relatives of the patients. We act here to produce this enzyme in our laboratory. we passed. " used the expressions.

"We are planning to deliver the prototype to the company after 3 years"

Binay, Greece and Finland partners work results in enzyme transporting the drug form and commercialization After obtaining points by transferring would be of a pharmaceutical company with the cooperation of Turkey, "the enzyme we've optimized the last stage in the bioprocess to deliver this pharmaceutical company and we aim to be released." he stated.

Stating that the duration of the project is 3 years, Binay said, "During this period, we will take many asparaginase enzymes from the organisms in nature and clone them. We will have a lot of asparaginase enzymes. We will obtain enzymes. At the end of the 3-year period, we will deliver the prototype we will produce to the pharmaceutical company we cooperate with. " he spoke.

Assoc. Dr. Binay pointed out that the unit costs of these drugs start from 800 euros and go up to 8 thousand euros. "According to the calculations we have made, we anticipate that we will reduce the cost of the drug we will produce locally by up to one eighth." said.

Lösemi tedavisinde kullanılacak 'yerli enzim' üretilecek

Gebze Teknik Üniversitesi bünyesindeki enzim tanıma laboratuvarında görev yapan araştırmacılar, lösemi hastaları için yurt dışından temin edilen asparaginaz enziminin Türkiye'de üretilmesi için kolları sıvadı. - Anadolu Ajansı

www.aa.com.tr